Please login to the form below

Not currently logged in
Email:
Password:

PD-1

This page shows the latest PD-1 news and features for those working in and with pharma, biotech and healthcare.

Sanofi completes acquisition of immuno-oncology specialist Synthorx

Sanofi completes acquisition of immuno-oncology specialist Synthorx

In the league of top pharma companies, Sanofi has been a bit late to the cancer immunotherapy category, but has been making a way into the market through its PD-1 ... inhibitor  Libtayo (cemiplimab) – the sixth PD-1/PD-L1 to reach the market.

Latest news

More from news
Approximately 26 fully matching, plus 326 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The confounding issue is that, in the case of PD-1/PD-L1 drugs, each developer uses its own companion diagnostic that is required to prescribe the drug. ... Harmonisation has been addressed in this case by the development of a ‘complementary’

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the ... hope was that - without the brake of PD-1 – the edited cells

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    However this class of drugs aren’t miracle cures: many patients and tumour types do not respond to PD-1/PD-L1s – the overall response rate (ORR) is commonly well below ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... 1 inhibitor Keytruda (pembrolizumab) was backed for cancers

  • Is China ready for a pharmaceutical gold rush?

    The programmed cell death 1 (PD-1) immune checkpoint inhibitor works by restoring the immune system’s ability to fight cancer tumours. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

More from intelligence
Approximately 0 fully matching, plus 34 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics